



Kristin Beale

Associate

kristin.beale@dlapiper.com

Boston

T: +1 617 406 6086

F: +1 617 406 6186

Dr. Kristin Beale works on a broad range of intellectual property matters with an emphasis on patent litigation.

Kristin has experience with Hatch-Waxman litigation, Inter Partes Review proceedings and trade secret litigation. She has represented clients across diverse industries in a wide array of technical fields, including agricultural technologies, pharmaceutical products, medical devices and gene editing technology.

- Patent Litigation
- Intellectual Property and Technology
- Life Sciences

Admissions

- Massachusetts

Prior Experience

Prior to practicing law Kristin was a postdoctoral fellow at Harvard University and Boston Children's Hospital where her projects focused on using a structural biology approach to develop malaria vaccines. Her graduate research projects at Brown University focused on the molecular mechanisms of gamete fusion and pollen genetics in flowering plants. She also worked as a research assistant at a marine functional genomics laboratory sequencing the lobster genome.

Education

- J.D., Boston College Law School 2018
- Ph.D., Brown University 2013
High Honors
National Science Foundation Graduate Research Fellow
- B.A., University of Maine Farmington 2007
cum laude

Courts

- United States Court of Appeals for the First Circuit
- United States Court of Appeals for the Third Circuit
- United States District Court for the District of Massachusetts

INSIGHTS

Publications

The Pharmaceutical Corner

30 March 2021

The opinion may render functional claiming more difficult, but functional claims that follow its guidance may still have an important role to play in pharmaceutical patents.

The Pharmaceutical Corner

22 December 2020

A precedential decision with potentially far-reaching impacts for future Hatch-Waxman litigation and generic-product launches.

Edwards Lifesciences v. Meril Life Sciences: Another ripple in the Safe Harbor?

26 October 2020

Navigating the contours of the Safe Harbor provision in view of recent Federal Circuit decisions will be a complicated, uncertain process.

- Syngenta Confirms Section 271(g) Infringement Does Not Require Single Entity Perform All Steps of Patented Method. December 24, 2019. JD Supra.com.

PRO BONO

Kristin has an active asylum pro bono practice.